Pronounced Regional Variation in Esketamine and Ketamine Prescribing to US Medicaid Patients
medRxiv Preprint Server April 23, 2022 Alexia G. Aguilar, Burke A. Beauregard, Christopher P. Conroy et al. 2 citations preprint
Background Ketamine and esketamine are efficacious for treatment resistant depression. Unlike other antidepressants, ketamine and esketamine lack a therapeutic delay and do not increase risk for suicidal thoughts and behaviors in adolescents and young-adults. Esketamine gained FDA approval in March of 2019.
DOI: 10.1101/2022.04.23.22274206 (opens in new tab)
Full text (opens in new tab)
Esketamine
Treatment-resistant depression
Depression treatment
Rapid-acting treatments
+14